CellCept and Myfortic medguides to be part of REMS
This article was originally published in Scrip
Executive Summary
New medication guides explaining birth defect and serious infection risks with two transplant drugs, Roche's CellCept (mycophenolate mofetil) and Novartis's Myfortic (mycophenolic acid), could be the first step toward more restrictive risk management measures for the immunosuppressants.